Detalhe da pesquisa
1.
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.
N Engl J Med
; 389(8): 710-721, 2023 Aug 24.
Artigo
Inglês
| MEDLINE | ID: mdl-37611121
2.
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.
Nature
; 575(7781): 217-223, 2019 11.
Artigo
Inglês
| MEDLINE | ID: mdl-31666701
3.
PI3Kα Translocation Mediates Nuclear PtdIns(3,4,5)P3 Effector Signaling in Colorectal Cancer.
Mol Cell Proteomics
; 22(4): 100529, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36931626
4.
CD74 is associated with inflamed tumor immune microenvironment and predicts responsiveness to PD-1/CTLA-4 bispecific antibody in patients with solid tumors.
Cancer Immunol Immunother
; 73(2): 36, 2024 Jan 27.
Artigo
Inglês
| MEDLINE | ID: mdl-38280003
5.
Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summary.
Future Oncol
; 20(3): 113-120, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-38010044
6.
A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours.
Br J Cancer
; 128(8): 1418-1428, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36797356
7.
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.
N Engl J Med
; 383(13): 1207-1217, 2020 09 24.
Artigo
Inglês
| MEDLINE | ID: mdl-32955176
8.
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors.
Cancer Immunol Immunother
; 72(7): 2443-2458, 2023 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-37016126
9.
Pexidartinib Provides Modest Pain Relief in Patients With Tenosynovial Giant Cell Tumor: Results From ENLIVEN.
Clin Orthop Relat Res
; 481(1): 107-116, 2023 01 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36001000
10.
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
N Engl J Med
; 381(17): 1632-1643, 2019 10 24.
Artigo
Inglês
| MEDLINE | ID: mdl-31566309
11.
Long-term outcomes of pexidartinib in tenosynovial giant cell tumors.
Cancer
; 127(6): 884-893, 2021 03 15.
Artigo
Inglês
| MEDLINE | ID: mdl-33197285
12.
Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities.
Cancer
; 127(16): 2934-2942, 2021 08 15.
Artigo
Inglês
| MEDLINE | ID: mdl-33910263
13.
Characterising the immune microenvironment in liposarcoma, its impact on prognosis and the impact of radiotherapy.
J Surg Oncol
; 123(1): 117-126, 2021 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-33084061
14.
Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial.
Acta Orthop
; 92(4): 493-499, 2021 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-33977825
15.
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.
Lancet
; 394(10197): 478-487, 2019 08 10.
Artigo
Inglês
| MEDLINE | ID: mdl-31229240
16.
Cost-effectiveness analysis of imaging surveillance in stage II and III extremity soft tissue sarcoma: an Australian perspective.
Cost Eff Resour Alloc
; 18: 5, 2020.
Artigo
Inglês
| MEDLINE | ID: mdl-32042270
17.
Utilisation of systemic therapy options in routine treatment of metastatic colorectal cancer in Australia.
Intern Med J
; 50(2): 165-172, 2020 02.
Artigo
Inglês
| MEDLINE | ID: mdl-30887616
18.
Systematic Review of Clinical Outcomes Following Various Treatment Options for Patients with Extraabdominal Desmoid Tumors.
Ann Surg Oncol
; 25(6): 1544-1554, 2018 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-29644533
19.
An Update on Immunotherapy for Solid Tumors: A Review.
Ann Surg Oncol
; 25(11): 3404-3412, 2018 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-30039324
20.
A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers.
Invest New Drugs
; 36(5): 886-894, 2018 10.
Artigo
Inglês
| MEDLINE | ID: mdl-29766337